tradingkey.logo

Sight Sciences Inc

SGHT
查看详细走势图
8.440USD
0.000
收盘 12/23, 16:00美东报价延迟15分钟
442.88M总市值
亏损市盈率 TTM

Sight Sciences Inc

8.440
0.000
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

0.00%

5天

+1.56%

1月

+16.25%

6月

+107.88%

今年开始到现在

+131.87%

1年

+136.41%

查看详细走势图

TradingKey Sight Sciences Inc股票评分

单位: USD 更新时间: 2025-12-22

操作建议

Sight Sciences Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名91/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价6.42。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Sight Sciences Inc评分

相关信息

行业排名
91 / 208
全市场排名
216 / 4578
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 7 位分析师
买入
评级
6.417
目标均价
-24.78%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Sight Sciences Inc亮点

亮点风险
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
业绩增长期
公司处于发展阶段,最新年度总收入79.87M美元
估值低估
公司最新PE估值-9.44,处于3年历史低位
机构减仓
最新机构持股26.78M股,环比减少27.62%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值3.89K

Sight Sciences Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Sight Sciences Inc简介

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
公司代码SGHT
公司Sight Sciences Inc
CEOBadawi (Paul)
网址https://www.sightsciences.com/

常见问题

Sight Sciences Inc(SGHT)的当前股价是多少?

Sight Sciences Inc(SGHT)的当前股价是 8.440。

Sight Sciences Inc的股票代码是什么?

Sight Sciences Inc的股票代码是SGHT。

Sight Sciences Inc股票的52周最高点是多少?

Sight Sciences Inc股票的52周最高点是8.800。

Sight Sciences Inc股票的52周最低点是多少?

Sight Sciences Inc股票的52周最低点是2.030。

Sight Sciences Inc的市值是多少?

Sight Sciences Inc的市值是442.88M。

Sight Sciences Inc的净利润是多少?

Sight Sciences Inc的净利润为-51.51M。

现在Sight Sciences Inc(SGHT)的股票是买入、持有还是卖出?

根据分析师评级,Sight Sciences Inc(SGHT)的总体评级为买入,目标价格为6.417。

Sight Sciences Inc(SGHT)股票的每股收益(EPS TTM)是多少

Sight Sciences Inc(SGHT)股票的每股收益(EPS TTM)是-0.894。
KeyAI